Biomx Inc represents a strong commitment to innovation, research, and breakthroughs in the field of microbiome therapeutics. The company's corporate philosophy is centered around developing personalized treatments to address unmet medical needs related to serious diseases and conditions caused by dysbiosis within the human microbiome. Biomx Inc strives to harness the power of the microbiome to improve patient outcomes and quality of life. Through cutting-edge technologies and strategic partnerships, Biomx Inc aims to advance the understanding and utilization of the microbiome, paving the way for innovative therapeutic solutions.

Biomx Inc is primarily present in the United States, with headquarters located in Ness Ziona, Israel.

Biomx Inc has achieved several significant milestones. The company has successfully developed a unique and innovative biotechnology platform that focuses on engineered phage products for the treatment of various diseases. Biomx Inc has also formed strategic partnerships with leading pharmaceutical companies, further enhancing their research and development capabilities. Notably, the company has advanced its clinical programs and successfully initiated Phase 1b/2a clinical studies, demonstrating promising results. Additionally, Biomx Inc has raised substantial funding through successful financing rounds, enabling them to support their cutting-edge research and reach key developmental targets. These achievements highlight Biomx Inc's commitment to advancing its novel therapeutic solutions and positioning itself as a key player in the biotechnology industry.

Biomx Inc is a biotechnology company specializing in the development of novel therapeutics using customized phage-based microbiome engineering. Founded in 2015, Biomx is dedicated to harnessing the power of the human microbiome to treat various diseases. With a focus on inflammatory bowel disease (IBD) and cancer, Biomx aims to revolutionize the field of microbiome-based therapeutics. Through their proprietary platform, Biomx engages in comprehensive research and development, leveraging cutting-edge technologies and scientific expertise. By understanding the intricate relationship between the human microbiome and diseases, Biomx is committed to delivering innovative, personalized therapies that have the potential to transform patient outcomes and improve lives.

The main competitors of Biomx Inc in the market include companies like Vedanta Biosciences, Seres Therapeutics, and Second Genome.

Biomx Inc is primarily active in the field of microbiome-based therapeutics.

Biomx Inc operates with a business model focused on the development of novel therapeutics using its proprietary microbiome-based technology platform. The company utilizes advanced computational tools and synthetic biology to identify and modify specific bacterial strains within the human microbiome, aiming to treat various diseases. By leveraging the potential of bacteria living within the body, Biomx Inc seeks to offer innovative solutions for conditions such as inflammatory bowel disease (IBD), cancer, and immuno-oncology. Through targeted modifications and interventions, Biomx Inc aims to harness the power of the microbiome to improve human health and address unmet medical needs.

Το Biomx P/E είναι -0,51.

Το KUV της εταιρείας Biomx είναι 0.

Το AlleAktien Qualitätsscore για το Biomx είναι 1/10.

Τα έσοδα δεν μπορούν να υπολογιστούν επί του παρόντος για Biomx.

Το αναμενόμενη Biomx κέρδος είναι -34,89 Εκ. USD.

The company Biomx Inc is a biotechnology company that specializes in the development and application of microbiome-related therapies. The various divisions of the company include research, development, and marketing of bacterial therapies and diagnostic tools for various diseases such as chronic inflammatory bowel disease, cancer, and skin diseases.

Η Biomx καταβάλλει μια διανομή της τάξεως των 0 USD διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το Biomx αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της Biomx είναι US09090D1037.

Το WKN της Biomx είναι A2P9A0.

Ο τίκερ της Biomx είναι PHGE.

Κατά τους τελευταίους 12 μήνες η Biomx κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η Biomx προβλέπεται να πληρώσει μέρισμα 0 USD.

Η απόδοση μερίσματος της Biomx ανέρχεται σήμερα στο .

Biomx πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η Biomx πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 USD. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το Biomx ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των Biomx από την 7/7/2024 με τιμή 0 USD, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 7/7/2024.

Η τελευταία μερίσματος έγινε στις 7/7/2024.

Το έτος 2023, η Biomx διένειμε 0 USD ως μερίσματα.

Τα μερίσματα του Biomx καταβάλλονται σε USD.